Seven Unanswered Questions About Blockbuster Weight-Loss Drugs
The race is on to develop the next generation of weight-loss drugs, with several promising candidates currently in Phase III clinical trials. These oral GLP-1 receptor agonists are vying for a share of the booming $126 billion obesity market. GLP-1 receptor agonists, like semaglutide, have already made waves in the weight-loss world. “Semaglutide is rocketing … Read more